Institutional equity research analysts covering NervGen Pharma maintain speculative consensus price targets that project potential valuation upside, heavily dependent upon the successful clinical advancement and future trial data readouts of its neuroreparative pipeline. Because clinical-stage biotechnology firms face high binary risks related to drug development and regulatory milestones, target forecasts carry wide valuation ranges.